Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for MaxCyte, Inc. (MXCT : NSDQ)
 
 • Company Description   
MaxCyte Inc. is a provider of cell-engineering enabling technology and is responsible cell-based therapies. MaxCyte Inc. is headquartered in Gaithersburg, Maryland.

Number of Employees: 84

 
 • Price / Volume Information   
Yesterday's Closing Price: $4.45 Daily Weekly Monthly
20 Day Moving Average: 621,816 shares
Shares Outstanding: 101.54 (millions)
Market Capitalization: $451.85 (millions)
Beta:
52 Week High: $17.44
52 Week Low: $4.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.29% -9.37%
12 Week -34.94% -29.41%
Year To Date -56.33% -48.07%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
22 FIRSTFIELD ROAD SUITE 250
-
GAITHERSBURG,MD 20878
USA
ph: 301-944-1700
fax: 301-944-1703
ir@maxcyte.com None
 
 • General Corporate Information   
Officers
Douglas Doerfler - Chief Executive Officer and President
Richard Douglas - Chairman
Ron Holtz - Chief Financial Officer
Ron Holtz - Senior Vice President and Chief Accounting Officer
Maher Masoud - Executive Vice President; General Counsel and Secr

Peer Information
MaxCyte, Inc. (CORR.)
MaxCyte, Inc. (RSPI)
MaxCyte, Inc. (CGXP)
MaxCyte, Inc. (BGEN)
MaxCyte, Inc. (GTBP)
MaxCyte, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 57777K106
SIC: 8731
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/12/22
Share - Related Items
Shares Outstanding: 101.54
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $451.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.28 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.72
Price/Cash Flow: -
Price / Sales: 11.59
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 20.00%
Sales Growth
vs. Year Ago Period: 78.40%
vs. Previous Quarter: 14.14%
ROE
03/31/22 - -7.39
12/31/21 - -11.11
09/30/21 - -14.74
ROA
03/31/22 - -6.78
12/31/21 - -10.18
09/30/21 - -13.03
Current Ratio
03/31/22 - 17.09
12/31/21 - 17.32
09/30/21 - 21.43
Quick Ratio
03/31/22 - 16.67
12/31/21 - 16.98
09/30/21 - 21.10
Operating Margin
03/31/22 - -41.15
12/31/21 - -56.30
09/30/21 - -52.27
Net Margin
03/31/22 - -41.15
12/31/21 - -56.30
09/30/21 - -52.27
Pre-Tax Margin
03/31/22 - -41.15
12/31/21 - -56.30
09/30/21 - -52.27
Book Value
03/31/22 - 2.58
12/31/21 - 2.61
09/30/21 - 2.63
Inventory Turnover
03/31/22 - 0.80
12/31/21 - 0.81
09/30/21 - 0.78
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©